# A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

> **NCT00283439** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 39 (actual)

## Conditions studied

- Chemotherapy-Induced Thrombocytopenia
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Cancer
- Oncology
- Thrombocytopenia

## Interventions

- **BIOLOGICAL:** AMG 531

## Key facts

- **NCT ID:** NCT00283439
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-05
- **Final completion:** 2008-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2011-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283439, "A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00283439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*